plants
Buying Iboga — What to Look For (Guide 2026)
Buying Iboga — What to Look For (Guide 2026) Iboga (Tabernanthe iboga) is a West African root bark with a long ritual tradition in Gabon and Cameroon. In Germany it is legally available — yet the market is opaque and quality varies enormously. This guide shows you what to pay attention to when buying iboga, which product forms exist, how to recognise reputable suppliers, and why lab analyses (COAs) are the central proof of quality. TL;DR — Buying iboga at a glance Iboga is legal in Germany — not controlled under BtMG or NpSG. Trade is permitted. Quality is decisive: authentic Tabernanthe iboga TA root bark from sustainable sources, ideally with a COA. Main forms: powder, capsules, whole/ground root bark, extract, and tincture — each with its own profile. COAs (Certificates of Analysis) document alkaloid content, identity, and purity (heavy metals, microbiology). Price orientation: powder from approx. €30–60/10 g, extracts and TA bark correspondingly higher. Reputability check: transparent origin, lab analyses, clear botanical designation, no healing claims. Is buying iboga legal in Germany? Yes. Iboga and its main alkaloid ibogaine are listed neither in the German Narcotics Act (BtMG) nor in the New Psychoactive Substances Act (NpSG). This means cultivation, possession, trade, and purchase of the plant and its preparations are fundamentally permitted. Unlike in the USA, France, Belgium, or Switzerland, there is no substance-law classification in Germany that restricts acquisition. Important to know: legal does not mean unregulated. As soon as a product is marketed as a medicinal product, food, or food supplement, other regulatory frameworks apply (LFGB, AMG). Reputable shops therefore sell iboga as a botanical sample or ethnobotanical collector's item — without healing claims, without dosage recommendations for human consumption. Details on the current legal situation — including international differences and travel aspects — can be found in our in-depth article on the legal status of iboga. Available forms: powder, capsules, root bark, extract, tincture If you want to order iboga, you will encounter five common product forms. They differ in processing, concentration, shelf life, and area of use (ritual, ethnobotanical, collector purposes). Iboga powder (ground root bark) Finely ground Tabernanthe iboga TA root bark. The TA designation (Total Alkaloid Root Bark) means the complete natural alkaloid spectrum is present — not just ibogaine, but also ibogamine, tabernanthine, and other secondary alkaloids. Buying iboga powder is the classic entry form: easy to measure, homogeneous, long shelf life when stored dry and dark. Iboga capsules (standardised powder) Powder in plant-based capsules (usually HPMC, occasionally gelatine). The advantage: consistent fill weight per capsule, no bitter taste, discreet handling. Anyone looking to buy iboga capsules should check for the alkaloid content per capsule — ideally confirmed by laboratory analysis. Capsules are particularly suitable for structured protocols. Iboga root bark (whole or coarsely ground) Whole bark pieces or shreds of TA root bark — the traditional form as used in the Bwiti ritual of Gabon. Visually recognisable by the characteristic yellowish-brown inner side and the light fibre pattern. Buying iboga root bark is the most authentic variant, but requires your own preparation (grinding, extraction) and presupposes appropriate knowledge. Iboga extract (concentrated alkaloid) An extract concentrated via solvent or water extraction. Extracts can be in the form of total-alkaloid extract (TA extract) or ibogaine HCl. The latter is highly pure (>98% ibogaine hydrochloride), usually as a white crystalline form. Extracts are considerably more potent than raw bark and are aimed at collectors who wish to document precise alkaloid quantities. Iboga extract is the product form with the highest purity and analytical requirements. Iboga tincture / iboga drops Alcohol- or glycerine-based extracts of the root bark. Tinctures offer a liquid, drop-accurate form of administration and keep well. Quality varies considerably: extraction medium, drug-to-extract ratio (DER), and alkaloid content should be clearly declared. A deeper overview of the activity spectrum and tradition can be found in the iboga guide. What distinguishes high-quality iboga products? The difference between a reputable and a questionable product is evident in several objective criteria: 1. Botanical identity. There are plants that can be confused with iboga, such as Voacanga africana, which look similar but have a different alkaloid profile. High-quality suppliers can confirm by HPLC or DNA analysis that the material is indeed Tabernanthe iboga. 2. Plant part. Only the root bark contains the desired alkaloid concentration. Stem wood, leaves, or mixed material are inferior. Reputable products are clearly declared as root bark or TA material. 3. Origin and sustainability. Iboga grows slowly. Wild harvesting in Gabon is under pressure — the CITES issue is being discussed internationally. Prefer suppliers who work with cultivated sources (e.g. from Cameroon, Ghana, or plantation projects) and provide proof of origin. 4. Alkaloid content. TA root bark typically contains 4–6% total alkaloids, 60–80% of which is ibogaine. Products with documented content are more transparent than those without analytics. 5. Processing and storage. Iboga should be gently dried, finely ground, and shipped in light-proof, airtight packaging. Moisture and UV light measurably reduce alkaloid content. 6. Freedom from contaminants. Heavy metals (lead, cadmium, arsenic, mercury), pesticide residues, and microbiological contamination (mould, E. coli) are real risks with unregulated raw material. Laboratory analyses are not optional here but mandatory. COAs and laboratory analyses: why they are decisive A Certificate of Analysis (COA) is the test protocol of an independent laboratory. For iboga it should show the following points: Identity: HPLC or HPTLC fingerprint confirming Tabernanthe iboga Alkaloid content: total alkaloids and ibogaine proportion in % or mg/g Secondary alkaloids: ibogamine, tabernanthine, ibogaline (profile confirms authenticity) Heavy metals: Pb, Cd, As, Hg — limits following EU pharmacopoeia logic Microbiology: total germ count, yeasts/moulds, pathogens Pesticides / residues: relevant depending on origin Batch number: traceability back to raw material Why this is central: Without a COA you are buying a black box. A brown powder can be anything — from genuine TA bark to adulterated Voacanga material. Ibogaine HCl that superficially looks white may be contaminated or underdosed. The laboratory report is the only objective quality criterion. At amama, laboratory analysis is standard: every iboga batch is tested for identity, alkaloid profile, and purity, and COAs can be viewed on request or via the product page. Typical price ranges by form (for orientation) The following price ranges are market observations for the German/European region 2025/2026. They serve as orientation — not as fixed prices. Product form Typical price range Iboga powder (TA root bark) approx. €30–60 / 10 g Iboga capsules (standardised) approx. €25–50 / 20–30 capsules Iboga root bark (whole/shreds) approx. €25–50 / 10 g Iboga extract (TA extract) approx. €60–150 / 5 g (depending on concentration) Ibogaine HCl (>98%) approx. €150–400 / 1 g Iboga tincture approx. €25–60 / 30–50 ml What influences the price? Origin (wild harvest vs. cultivation), alkaloid content, laboratory documentation, batch size, shipping costs, and customs handling. Strikingly cheap offers — especially from unclear online sources — are often a warning sign: either mixed-up material, old batches with degraded alkaloids, or unregistered grey imports. A fair price lies in the middle range. Those offering considerably less typically save on analytics, proof of origin, or purity. What to look for in online shops (reputability check) An iboga shop is only as good as its transparency. This checklist helps you distinguish trustworthy from problematic suppliers: ✅ Imprint and registered office in the EU. Clear company name, valid service address, VAT ID. Shops without an imprint should be avoided. ✅ Clear botanical designation. Tabernanthe iboga, part of the plant (root bark), country of origin. No fantasy names. ✅ COAs available. Either linked directly on the product page or viewable on request. Batch and date traceable. ✅ No healing claims. Reputable suppliers sell iboga as a botanical sample or ethnobotanical product — not as a therapy against addiction, depression, or other conditions. Anyone making such claims is operating in a legal grey area and signals unreliability. ✅ Transparent shipping and return conditions. T&Cs, right of withdrawal, shipping country. ✅ Reachable customer service. Email, ideally telephone. Response within a few working days. ✅ Payment methods with buyer protection. SEPA, credit card, PayPal. Exclusively crypto payment without alternatives is a warning sign. ✅ Age verification. Reputable ethnobotanical shops check for age of majority. ❌ Warning signs: no contact details, only crypto payment, absurdly low prices, healing claims, missing COAs, conspicuous spelling errors, stock photos as product images, "directly from Africa" without any analytics. The entire iboga collection at amama is curated according to these principles: botanically verified, lab-tested, transparently documented. Common mistakes when buying iboga 1. Putting price before quality. The difference between €40 and €25 per 10 g of powder is often the difference between tested TA bark and anonymous raw material. With such a complex plant, this is not a sensible saving. 2. Not requesting a COA. Many buyers never ask for laboratory analyses. Reputable suppliers provide them — a shop that evades this is a bad sign. 3. Confusion with Voacanga. Voacanga africana is occasionally sold as "iboga" but contains a different alkaloid profile (mainly voacangine, hardly any ibogaine). Not distinguishable without analytics. 4. Grey-market sources from social media. Offers via Telegram, WhatsApp, or closed forums bypass all quality control. Legally risky, health-wise incalculable. 5. Confusing ibogaine HCl with TA bark. Ibogaine hydrochloride is an isolated pure substance and has a completely different concentration profile than root bark. They are not interchangeable. 6. Incorrect storage after purchase. Iboga loses alkaloids through light, heat, and moisture. Storage: dark, dry, airtight, cool. 7. No engagement with interactions. Iboga has a relevant pharmacological interaction profile (including hERG channel, CYP2D6). Anyone interested in microdosing should read the iboga microdosing fundamentals before ordering. 8. Ignoring the ritual context. Iboga is not a lifestyle substance. Anyone acquiring it should know and respect the cultural background (Bwiti tradition, sustainability questions). FAQ 1. Is it legal to order iboga in Germany? Yes. Iboga and ibogaine are subject to neither the BtMG nor the NpSG in Germany. Import from EU countries is unproblematic; for third countries, customs may ask additional questions. 2. Which iboga form is best? "Best" depends on purpose. TA root bark / powder offers the complete alkaloid spectrum. Capsules are practical for structured protocols. Extracts are interesting for collectors who want precise concentrations. For newcomers to the topic, powder or capsules with a COA are the most transparent. 3. What is the difference between TA bark and ibogaine HCl? TA bark (Total Alkaloid Root Bark) contains the natural alkaloid spectrum (~4–6% total alkaloids). Ibogaine HCl is the isolated, crystalline main alkaloid at high purity (>98%). They are not pharmacologically identical and not 1:1 interchangeable. 4. How do I recognise a reputable COA? A genuine COA bears the name and accreditation of an independent laboratory, a batch number, an analysis date, and specific measured values (not just "passed"). Generic PDFs without a laboratory letterhead are worthless. 5. Can I also buy iboga in pharmacies? No. Iboga is not an approved medicinal product in Germany and is therefore not distributed via pharmacies. Sales take place exclusively through specialist ethnobotanical retailers. 6. How long does iboga keep? With correct storage (dark, dry, airtight, cool), TA powder retains its alkaloid content for at least 2–3 years. Extracts and ibogaine HCl are stable even longer under the same conditions. Moisture and UV are the biggest enemies. 7. Are there reputable iboga retreats in Germany or Europe? In Germany there are no classic iboga retreats, as therapeutic offerings are legally restricted. In parts of Europe (e.g. the Netherlands, Portugal) there are providers with medical supervision. Selection requires thorough research — medical screening (ECG, liver values, medication review) is non-negotiable. 8. Why is amama a reputable source? amama is a Berlin smartshop focused on ethnobotany and laboratory analytics. Every iboga batch is tested for identity, alkaloid profile, and purity; COAs can be viewed; origin and processing are documented. Sales are made exclusively to customers of legal age, without healing claims, as an ethnobotanical collector's item. Related content Iboga guide: tradition, pharmacology, application Legal status of iboga in Germany and internationally Iboga microdosing: fundamentals and context Ready to order iboga in verified quality? In the [amama iboga shop](/collections/iboga) you will find carefully curated iboga products — TA root bark, powder, capsules, and extracts — with botanical verification, complete laboratory analytics, and transparent origin. Shipping from Berlin, discreet packaging, age verification, buyer protection. [To the iboga collection →](/collections/iboga) This article serves informational and consumer-protection purposes. It contains no dosage recommendations for human consumption. Iboga products are offered as botanical samples or ethnobotanical collector's items. Sale exclusively to persons aged 18 and over. → Ibogaine Compound Profile — chemistry, pharmacology & references
Learn moreIboga vs. Psilocybin: Differences, Similarities and Areas of Application
This article is part of our [Iboga Guide](https://amama.space/blogs/plants/iboga-guide). TL;DR — Iboga and Psilocybin at a Glance > Iboga (Tabernanthe iboga) and psilocybin mushrooms are two of the most intensively researched plant-based entheogens of our time. They act on entirely different receptor systems, have different traditions and different clinical application profiles. Both are available in Germany in their natural, botanical form — with different legal nuances. > Mechanism of action: Ibogaine acts multi-receptorally (SERT, NMDA, κ-opioid, σ-2); psilocybin primarily as a 5-HT2A agonist. Experience duration: Iboga 24–36+ hours; psilocybin 4–6 hours. Safety: Ibogaine requires cardiac screening (ECG); psilocybin has a minimal cardiac risk profile. Research focus: Iboga → opioid dependence, PTSD, TBI; psilocybin → depression, anxiety, addiction. Legal status DE: Both available in natural form — iboga fully legal, psilocybin mushrooms in a legal grey area. At a Glance: The Direct Comparison Criterion Iboga Psilocybin Botanical source Tabernanthe iboga Psilocybe mushrooms Origin Central Africa (Gabon, Cameroon) Worldwide distribution Main alkaloid Ibogaine (tryptamine indole alkaloid) Psilocybin → psilocin Mechanism of action SERT, NMDA, κ-opioid, σ-2 5-HT2A agonism Experience duration 24–36+ hours 4–6 hours Traditional context Bwiti religion (initiation) Mesoamerican (Mazatec) Primary research indication Addiction treatment, PTSD, TBI Depression, anxiety, addiction Legal status DE ✅ Legal (plant & ibogaine) ✅ Mushrooms in natural form (grey area) Cardiac risk Yes — ECG required Minimal Intensity Very high Moderate to high Phenomenology Oneirogenic, introspective Visual, transpersonal Mechanism: Why They Work So Differently Perhaps the most important difference between iboga and psilocybin lies at the molecular level — and it explains why the two experiences differ so fundamentally. Psilocybin is a classical psychedelic in the strict sense. After oral ingestion, it is dephosphorylated to psilocin, which acts as a partial agonist at the serotonin 5-HT2A receptor. This receptor is considered a central switching point for the characteristic psychedelic phenomenology: visual intensification, ego dissolution, transpersonal experiences, synaesthetic perception. Studies suggest that 5-HT2A agonism dampens the so-called Default Mode Network (DMN) and temporarily rewires neural networks. Ibogaine, by contrast, is not a classical psychedelic. It binds to an unusually broad range of receptors: it inhibits the serotonin transporter (SERT), antagonises NMDA receptors (similar to ketamine), acts as a κ-opioid receptor agonist, and binds to σ-2 receptors. The active metabolite noribogaine has a longer half-life and contributes to the delayed, days-long lingering effect. Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Compound profile: Ibogaine → Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Read more about Ibogaine → This multi-receptoral activity leads to an experience that researchers often describe not as "psychedelic" in the classical sense, but as oneirogenic — dreamlike, introspective, film-like, with biographical memory sequences. Users report fewer classical visual hallucinations and more of a "life review" phenomenon. What both substances have in common: in preclinical studies, both ibogaine and psilocybin have been shown to promote neuroplasticity (BDNF expression, synaptic reorganisation) — albeit through different molecular pathways. The "reset" hypothesis (Alper 2012) posits that ibogaine specifically interrupts addiction-related neural pathways. Areas of Application Compared Both substances show promise in clinical studies — but for different indications. Where Iboga Is in the Research Spotlight Opioid dependence: Ibogaine is known for its ability to drastically reduce withdrawal symptoms in a single session. Treatment centres in Mexico, the Netherlands and Portugal use this clinically. Complex trauma & TBI: The Stanford study (Cherian et al., Nature Medicine 2023) examined 30 US military veterans with traumatic brain injury. The combination of ibogaine + magnesium showed significant improvements in PTSD, depression and anxiety. Severe addiction disorders: Methamphetamine, cocaine, alcohol — especially where classical approaches have repeatedly failed. Where Psilocybin Is in the Research Spotlight Treatment-resistant depression: COMPASS Pathways and other Phase 3 studies show significant effects after a single session. End-of-life anxiety: Johns Hopkins and NYU documented clear, long-lasting reductions in existential anxiety in cancer patients. Smoking cessation: Matthew Johnson et al. (Johns Hopkins) showed high abstinence rates after 6 months. Obsessive-compulsive disorder (OCD): Early studies suggest potential. Overlapping Indications PTSD Alcohol dependence Major depression The choice between iboga and psilocybin is therefore strongly context-dependent: the specific indication, physical condition, availability of medical infrastructure, and the individual's readiness for a multi-day versus multi-hour experience. From the archive Tabernanthe iboga — botanical specimen · Ji-Elle · 2018-05-24 Tabernanthe iboga plant at the Meise Botanic Garden, Belgium. Jardin botanique de Meise · CC BY-SA 3.0 Experience Duration: A Decisive Factor The difference in duration is not trivial — it determines protocol, setting and suitability. Iboga experience: 24–36+ hours A Bwiti initiation or a clinical ibogaine session extends over at least one day and one night. The phase of intense visions often lasts 8–12 hours, followed by an "introspection" or "grey-day" phase of another 12–24 hours. Physically, the experience is demanding: ataxia (inability to move), nausea and light sensitivity are typical. Sleep can be disturbed for several days. Psilocybin experience: 4–6 hours A classical psilocybin session has an onset phase of about 30–60 minutes, a peak of 2–3 hours and a come-down phase. Sleep is usually possible on the same night. The experience is intense but manageable in time. This difference explains why clinical psilocybin protocols often work in a single-day format, whereas ibogaine treatments require multi-day inpatient settings with overnight stays and medical monitoring. Safety Profile Here the arguably most important practical difference becomes apparent. Ibogaine: Cardiac Monitoring Mandatory Ibogaine prolongs the QT interval in the heart and can, in rare cases, lead to dangerous arrhythmias. According to data from the Global Ibogaine Therapy Alliance (GITA, 2015), approximately 1 in 300 cases without cardiac screening may be potentially life-threatening. Responsible use requires: ECG before the session Electrolyte check (potassium, magnesium) Liver values Exclusion of pre-existing cardiac conditions Medically supervised setting Clarification of all drug interactions (especially SSRIs, MAO inhibitors, opioids, QT-prolonging medications) Psilocybin: Minimal Cardiac Risk Psilocybin has a remarkably favourable physiological safety profile. It is neither nephro- nor hepatotoxic, causes no cardiac conduction disturbances and no physical dependence. The risks are almost exclusively psychological in nature: challenging experiences ("bad trips"), risk for those predisposed to psychosis, HPPD (Hallucinogen Persisting Perception Disorder) in isolated cases. In Common: Set & Setting Both substances require careful preparation, a trusting environment and competent guidance. For iboga this is non-negotiable for medical reasons; for psilocybin, for psychological ones. Anecdotal reports and initial long-term observations suggest that the longer and more intense iboga experience may enable deeper and more lasting transformations in suitable candidates — a price paid with higher physical risk and considerably more elaborate medical infrastructure. Legal Status: What Is Allowed Where? Both substances are in a legally interesting position in Germany — with important differences. Iboga & Ibogaine in Germany: Fully Legal Neither Tabernanthe iboga (the plant, root bark, seeds) nor ibogaine (the isolated alkaloid) are listed in the Narcotics Act (BtMG, annexes I–III) or in the New Psychoactive Substances Act (NpSG) (as of April 2026). This means: possession, purchase and sale as an ethnobotanical collector's item are legal. Ibogaine is not approved as a medicinal product in Germany — it is not sold as a food or medicine, but as a traditional botanical product. More on this: Iboga Legal Status Germany. Psilocybin Mushrooms: More Nuanced The legal situation for Psilocybe mushrooms is more differentiated: Isolated psilocybin and dried fruiting bodies are listed in BtMG Annex I — prohibited. Fresh, naturally growing mushrooms have not been unambiguously assessed as subject to the BtMG in some rulings — a grey area that is interpreted differently depending on the federal state and individual case. Spores and cultures are generally legal, as they themselves contain no psilocybin. European Overview Country Iboga/Ibogaine Psilocybin mushrooms Germany ✅ Legal ⚠️ Grey area (fresh), prohibited (dried) Netherlands ✅ Legal (treatment centres) ✅ Truffles legal Portugal ✅ Legal (retreats) Decriminalised Switzerland ❌ Prohibited ❌ Prohibited France ❌ Prohibited ❌ Prohibited Belgium ❌ Prohibited ❌ Prohibited German-speaking individuals seeking a guided ibogaine or psilocybin experience typically travel to the Netherlands or Portugal. Conclusion: Which Substance for Whom? Neither iboga nor psilocybin is "better" — both substances have distinct profiles and are suited to different situations. Iboga may be relevant in a research context for: Severe, long-term addiction (especially opioids) Complex trauma-related disorders, TBI Situations where classical therapy has repeatedly failed Willingness to undergo a multi-day, physically demanding setting with medical monitoring Psilocybin may be relevant for: Treatment-resistant depression Existential anxiety, end-of-life contexts Smoking cessation, alcohol problems Desire for a shorter, time-limited experience Pre-existing cardiac conditions that rule out ibogaine The choice is a clinical, personal and contextual one. Both substances deserve respect — not hype. Neither is a "miracle cure", and both require serious preparation and competent guidance. An often overlooked point: iboga is the legally clearer option in Germany. While psilocybin mushrooms exist in a fragile grey area, Tabernanthe iboga is unambiguously legally available as an ethnobotanical product — which explains why interest among German collectors and researchers in this plant has risen sharply in recent years. Our selection Iboga Tabernanthe iboga is a perennial rainforest shrub native to Central Africa, particularly Gabon and Cameroon, where it has been used for centuries in Bwiti initiation ceremonies. The root bark… → Shop the collection Back to the Overview Back to the Iboga Guide | Iboga Effects | Iboga Legal Status | Iboga Therapy Last updated: April 2026. This content is for informational purposes only and does not constitute medical advice. → Ibogaine Compound Profile — chemistry, pharmacology & references
Learn more
Ibogaine Therapy in Europe: Clinics, Research Status and Safety
This spoke is part of our Iboga Guide. TL;DR — Ibogaine Therapy in Europe Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Read more about Ibogaine → > Ibogaine, the main alkaloid of the Central African plant Tabernanthe iboga, has been researched since the 1980s in medically supervised settings for the treatment of opioid dependence, alcoholism, PTSD and treatment-resistant depression. In Germany, ibogaine is not approved as a medicine, so German-speaking patients typically travel to legal treatment centers in Portugal, Spain or the Netherlands. Due to serious cardiac risks (QT prolongation), a complete medical screening before any use is indispensable. > Main indications in research: opioid detox, alcohol dependence, PTSD, treatment-resistant depression, TBI rehabilitation Mechanism of action: "neuronal reset" via GDNF normalization, serotonergic modulation, memory reconsolidation European options: Tabula Rasa Retreat (Portugal), Madera Sagrada (Spain), several Amsterdam clinics (Netherlands) Mandatory screening: ECG, liver values, medication history, psychiatric evaluation Risk without screening: approx. 1 in 300 cases potentially life-threatening (GITA data) What is ibogaine used for therapeutically? Clinical research on ibogaine focuses on indications where conventional therapies often reach their limits — particularly chronic addictive disorders and trauma-related conditions. Characteristically, even a single supervised session has shown long-lasting effects in several observational studies, whereas many standard therapies rely on permanent medication. Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Compound profile: Ibogaine → Indication Research Status Evidence Level Opioid dependence (withdrawal interruption) Mash et al. (2018, St. Kitts cohort, n=191); Noller et al. (2018, New Zealand cohort, 12-month follow-up) Observational studies, no RCT Alcohol dependence Preclinical (Carnicella et al. 2010); smaller case series Early PTSD / trauma (veterans) Cherian et al. (2023, Stanford, Nature Medicine, n=30) — ibogaine + magnesium, significant reduction of PTSD, depression, anxiety, disability Open-label, pilot study Treatment-resistant depression Alper et al. (2012) — review; MAPS-funded follow-up studies ongoing Early TBI (traumatic brain injury) Stanford 2023 — veterans with traumatic brain injury Early, exploratory The Stanford study (Cherian et al. 2023) is so far the methodologically most robust data point: 30 US veterans with combined diagnoses (PTSD, depression, TBI) received ibogaine together with intravenous magnesium at a Mexican clinic. The effect sizes after one month were unusually large — however, this is an uncontrolled observation, not a randomized trial. A follow-up study with a control group is in preparation. The neurobiological reset: how ibogaine affects addiction pathways The so-called "neuronal reset" hypothesis (Alper 2012) describes why a single ibogaine session can produce effects that repeated doses of other substances fail to achieve. Several mechanisms presumably interact: GDNF restoration. Carnicella et al. (2010) showed in animal models that ibogaine increases the concentration of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA). GDNF stabilizes dopaminergic neurons whose signaling becomes dysregulated by chronic substance use. This may explain why craving for opioids and alcohol measurably decreases after a single session. Serotonergic normalization. Ibogaine acts as a serotonin reuptake inhibitor and modulates several 5-HT receptors. Combined with its NMDA-antagonistic action, this yields a profile with parallels to ketamine — but with a significantly longer duration of action (12–36+ hours). Memory reconsolidation via sigma-2 receptors. Ibogaine shows pronounced affinity for the sigma-2 receptor, which is involved in memory processes and emotional processing. Studies suggest that during the active window, traumatic and addiction-associated memories may be re-"stored" in a plastic state — a process that many treated individuals subjectively describe as an intense life review. Noribogaine as long-term metabolite. The liver metabolite noribogaine is pharmacologically active, has a half-life of several days, and is considered co-responsible for the sustained anti-craving window following the acute session. From the archive Tabernanthe iboga — botanical specimen · Ji-Elle · 2018-05-24Tabernanthe iboga plant at the Meise Botanic Garden, Belgium.Jardin botanique de Meise · CC BY-SA 3.0 Treatment options in Europe (for German-speaking patients) Since ibogaine is not approved as a medicine in Germany (but is legally possessable — neither Tabernanthe iboga nor ibogaine are listed in the BtMG or NpSG), therapeutic use takes place almost exclusively abroad within Europe. The following centers are considered established and work with medical personnel and cardiac screening: Center Country Specialization Note Tabula Rasa Retreat Portugal (Sintra) Addiction, PTSD, depression Medically supervised, mandatory cardiac screening, structured integration Madera Sagrada Spain (Órgiva) Addiction, trauma Ceremonial + therapeutic programs, Bwiti influences Amsterdam clinics Netherlands Opioid detox, depression Ibogaine legal, several centers, often physician-led Iboga Life / ex-Sanandao network Portugal / Netherlands Addiction International orientation Belgium, France, Switzerland, the United Kingdom, Ireland, Sweden and Norway have banned ibogaine — treatment is not legally possible there. What patients can expect: a typical process 1. Intake and pre-screening (weeks in advance). Medical history, medication list, psychiatric assessment. Many centers require a current cardiology report including 12-lead ECG, liver values, kidney function and a pregnancy test. QT-prolonging medications (certain antidepressants, antibiotics, antipsychotics) are absolute exclusion criteria if they cannot be discontinued in time. 2. Medication tapering. SSRIs, SNRIs, MAO inhibitors and opioid agonists (methadone, buprenorphine) must be discontinued before the session or switched to short-acting substitutes. This is done under medical supervision, often over 2–6 weeks. 3. Arrival and on-site check (1–2 days). Repeat ECG, blood pressure baseline, electrolyte check (especially potassium and magnesium). Psychological preliminary interview, goal setting. 4. Treatment day. The session takes place in a quiet, darkened room with medical personnel present. Continuous ECG monitoring over 12–24 hours is standard. The acute effect lasts 8–12 hours, subtle after-effects 24–36 hours. 5. Follow-up observation (at least 24h). Transition into a rest phase. No being alone during the first 48 hours. 6. Integration. Reputable centers offer several integration sessions — on-site and/or remotely in the weeks after. The length of stay is typically 5–7 days minimum, longer in complex cases. Safety protocol: what every reputable clinic must ensure The Global Ibogaine Therapy Alliance (GITA) published guidelines in 2015 that today represent the international de facto standard. A responsible clinic meets at least the following criteria: Complete cardiac assessment: 12-lead ECG with QTc measurement, echocardiogram if structural heart disease is suspected, electrolyte status Medication history and tapering under medical supervision Exclusion criteria: current SSRI/SNRI use, opioid agonists without switching, severe liver/kidney disease, pregnancy, active psychosis, long QT syndrome, severe coronary heart disease Psychological evaluation before treatment Presence of a physician or emergency paramedic throughout the entire acute phase Continuous cardiac monitoring at least during the first 12 hours Emergency equipment (defibrillator, IV magnesium, advanced resuscitation medication) Structured integration after the session From the known fatalities of recent decades (Alper et al. 2012, retrospective analysis), it can be inferred: approximately 1 in 300 cases without adequate cardiac screening can potentially be life-threatening. The majority of these events occurred in underground settings with unknown health status, mixed consumption or QT-prolonging medications that had not been discontinued. Ibogaine therapy should take place exclusively in medically supervised settings with complete cardiac screening. Underground sessions, weekend "retreats" without a physician and self-administration are not serious options — regardless of the substance's legal status. Excursus: Bwiti ceremonies vs. clinical application Traditional Bwiti initiation in Gabon and Cameroon and clinical ibogaine treatment are historically related but structurally different practices. One is not a substitute for the other. Aspect Bwiti ceremony Clinical ibogaine therapy Substance Crushed root bark, full alkaloid complex Isolated ibogaine HCl (pharmaceutical purity) Setting Community house, drums, singing, Nganga (ceremony leader) Clinic room, medical monitoring, therapists Objective Spiritual initiation, ancestor contact, rite of passage Symptom reduction, craving interruption, trauma processing Framework interpretation Religious-cosmological Clinical-psychological Duration Often 2–3 days 1 day acute + integration Risk profile Depends on participants' health; traditionally without ECG Medically secured Both contexts are legitimate within their respective traditions. Western patients seeking a therapeutic intervention, however, should clearly distinguish between ceremonial and clinical ibogaine use — and honestly assess which framework suits their concern and state of health. Some European centers (such as Madera Sagrada) deliberately work with hybrid formats, combining ceremonial elements with medical safeguards. Outlook: Will ibogaine come to Germany? The regulatory landscape has changed significantly between 2023 and 2026. Several developments suggest that ibogaine will come into greater focus of European regulatory authorities in the coming years: Stanford 2023 delivered the first high-quality pilot study in a Western academic context Texas approved 100 million US dollars for ibogaine research in 2025 — the largest single psychedelic research funding in US history Trump's Executive Order of April 18, 2026 mandates the FDA with an accelerated review procedure for ibogaine MAPS and other organizations are advancing clinical Phase II studies For German approval, the realistic path would be: EMA-compliant Phase II and Phase III studies (usually 3–6 years) BfArM review following successful EMA evaluation Pilot programs in university clinics, possibly initially within the framework of compassionate use regulations (§ 41 AMG) The Netherlands and Portugal could serve as EU-internal model states, since clinical infrastructure and experience already exist there A realistic forecast: 5–10 years until a possible regular approval of ibogaine as a medicine in Germany — provided that the ongoing Phase II studies deliver positive safety and efficacy data. Until then, the legal situation remains as it is: ibogaine is legally possessable in Germany, but not an approved medicine, and therapeutic use takes place abroad within Europe. Back to the overview Back to the Iboga Guide | Iboga Effects | Iboga Legal Status 2026 | Iboga vs. Psilocybin Collection Iboga Tabernanthe iboga is a perennial rainforest shrub native to Central Africa, particularly Gabon and Cameroon, where it has been used for centuries in Bwiti initiation ceremoni… → Shop the collection Last updated: April 2026. This content is for informational purposes only and does not constitute medical advice. Not a medical product. For medical questions, please consult a physician. → Ibogaine Compound Profile — chemistry, pharmacology & references
Learn moreIboga & Legal Status 2026: What Trump's Executive Order Means for Germany
This post is part of our [Iboga Guide](https://amama.space/blogs/plants/iboga-guide). TL;DR — Iboga is legal in Germany, and the broader political climate is shifting dramatically in 2026. On 18 April 2026, US President Donald Trump signed an Executive Order accelerating the FDA review of psychedelics — explicitly including ibogaine. For Germany, this means no immediate legal change, but massive research and evidence pressure on the EMA and BfArM. Here is the current context at a glance. ✅ Germany: Tabernanthe iboga and ibogaine are listed neither in the BtMG nor in the NpSG — legal as a botanical. USA (April 2026): Trump EO accelerates FDA review of ibogaine; USD 50 million via ARPA-H; Joe Rogan was present at the signing. Treatment access: The Netherlands and Portugal offer medically supervised programs — German patients increasingly travel there. ⚠️ Safety: Ibogaine may prolong the QT interval. Potentially life-threatening without cardiological screening (approximately 1 in 300 cases in older case series). amama position: We sell iboga root bark as a traditional ethnobotanical — not a medicine, not a food, not a therapy referral. Current Developments (Newsfeed) 18 April 2026 — Trump signs Executive Order on psychedelics (incl. ibogaine) > US President Donald Trump signed an Executive Order accelerating FDA review of psychedelics — including ibogaine, psilocybin, LSD, MDMA and ketamine — for psychiatric indications. The order allocates USD 50 million via the Advanced Research Projects for Health (ARPA-H) program and opens a path to approval under the "Right to Try Act". Joe Rogan was present at the White House signing — he had previously alerted Trump to ibogaine via text message. Trump's reply, according to Fortune Magazine: "Sounds great. Want FDA approval? Let's do it." Ibogaine remains Schedule I for now — but the EO creates research and access corridors. > Source: CNBC, 18 April 2026 | White House Fact Sheet 1 April 2026 — Joe Rogan Experience #2477: Rick Perry & Bryan Hubbard on the Texas Ibogaine Initiative > Former Texas Governor Rick Perry and activist W. Bryan Hubbard discussed the Texas Ibogaine Initiative on JRE #2477 — the largest state-level psychedelics research program in US history. Texas had already committed USD 100 million to ibogaine research in 2025. Perry: "Ibogaine has the potential to solve our veterans crisis." Rogan: "This is one of the most important shows I've ever done." The episode was streamed over 10 million times within 48 hours and brought ibogaine into mainstream discourse. 2025 — Stanford study: Ibogaine in war veterans with PTSD and traumatic brain injury > A study by Stanford University (Cherian et al., Nature Medicine, 2023, extended with follow-up data in 2025) examined 30 US military veterans with PTSD, depression and traumatic brain injury. A single ibogaine session (with magnesium supplementation to mitigate cardiac risk) led to significant improvement of PTSD symptoms, which persisted for months after treatment. The study is the most robust clinical signal to date for ibogaine's psychiatric potential in severe trauma cases. 2025 — Texas: USD 100 million for ibogaine — largest US psychedelics program > Under Governor Greg Abbott, Texas became the first US state to allocate USD 100 million in public funds for ibogaine research — more than any other state-level psychedelics initiative worldwide. The focus: veterans with PTSD and opioid dependence. In parallel, 181 Texas legislators backed an initiative for ibogaine decriminalization. November 2025 — Germany: Ibogaine still NOT in BtMG or NpSG > The German Federal Ministry of Health confirmed in response to a parliamentary inquiry that neither Tabernanthe iboga nor ibogaine is listed in the annexes of the Narcotics Act (BtMG) or the New Psychoactive Substances Act (NpSG). No applications for inclusion are pending. Iboga remains legally tradeable in Germany as a traditional plant — though not as a medicine or food. Legal Status in Germany: What Is Permitted? The German legal situation regarding iboga is clear, if surprising to many: Neither the plant Tabernanthe iboga nor its main alkaloid ibogaine is prohibited in Germany. Both are listed neither in Annexes I, II or III of the Narcotics Act (BtMG) nor in the New Psychoactive Substances Act (NpSG). This sets iboga apart from almost all other classical psychedelics — psilocybin, LSD, DMT and mescaline are all BtMG-listed in Germany. What does this mean in practice? Possession, purchase and sale of iboga root bark as a botanical product are legal. Not approved as a medicinal product: Physicians may not prescribe ibogaine in Germany, as it has no approval under the Medicines Act (AMG). Not approved as a food or dietary supplement: It may not be advertised with health claims (Health Claims Regulation, Novel Food Regulation). Isolated ibogaine: If placed on the market as a medicinal product (e.g. with healing claims), the AMG applies — then sale without approval would not be permissible. As a reference substance for research or as a collector's item, the situation is less clear-cut. amama sells iboga root bark exclusively as a traditional ethnobotanical product — without medicinal or dietary intended purpose. Legal Overview at a Glance Status Germany Possession ✅ Legal Purchase ✅ Legal Sale as botanical ✅ Legal As a medicine ❌ Not approved As a food ❌ Not approved Medical therapy ❌ No approval This constellation — legal botanical, but no medical approval — is typical for many ethnobotanical plants (cf. kratom, kanna, blue lotus). It opens up a legal collector and research space, while therapeutic applications are outsourced abroad. European Legal Landscape Overview Europe is divided on iboga. While some countries traditionally take a liberal approach to ethnobotanical substances, others have explicitly banned iboga — often following isolated deaths at unregulated retreats. Country Status Note Germany ✅ Legal Not in BtMG/NpSG Netherlands ✅ Legal Treatment centres active Portugal ✅ Legal Retreat clinics (Tabula Rasa Retreat, Sintra) Spain ✅ Legal Madera Sagrada Retreat (Órgiva) Switzerland ❌ Banned Federal Narcotics Act Belgium ❌ Banned Safety concerns France ❌ Banned Since 2007 (stupéfiant list) Norway ❌ Banned Sweden ❌ Banned Ireland ❌ Banned United Kingdom ❌ Banned Psychoactive Substances Act 2016 Particularly relevant for German-speaking patients: Austria does not explicitly address ibogaine in its Narcotic Substances Act, though interpretation is inconsistent. In Switzerland, ibogaine has been listed in the Federal Narcotics Act for years and is therefore illegal. From the archive Iboga root bark pieces · Kim Gjerstad · 2011-11-22 Dried root bark pieces of Tabernanthe iboga — the primary traditional preparation used in Bwiti ceremony. Wikimedia Commons · CC BY-SA 4.0 What Does Trump's Executive Order Mean for Europe? The US Executive Order of 18 April 2026 formally changes nothing under European law. US orders have no extraterritorial effect on the EMA, BfArM or national legislators. The indirect impact, however, is considerable: 1. Accelerated clinical evidence. The EO unlocks USD 50 million in ARPA-H funding and fast-tracked FDA procedures. The resulting Phase II and Phase III studies automatically become part of the global evidence base that the European Medicines Agency (EMA) evaluates in its own approval processes. MAPS and related consortia have already signalled that they will include European study sites. 2. Precedent pressure on EU member states. If the FDA approves ibogaine for opioid dependence or PTSD, political pressure will build on European authorities not to withhold access indefinitely — especially if German veterans and addiction patient groups cite US data. 3. Research funding. US funding increases global academic capacity. German universities (including Charité and Heidelberg University) are already actively monitoring the psychedelics field; the Stanford data are increasingly cited in European reviews. 4. Netherlands and Portugal as observation zones. Both countries have liberal regulations and active treatment centres. They could — similar to MDMA-assisted therapy — serve as European pilot regions long before Germany takes formal steps. 5. Patient advocacy. In Germany, smaller groups (especially from the Bundeswehr and opioid-withdrawal communities) have organised to push for legal therapeutic access. US developments reinforce their arguments. What Could a German Approval Pathway Look Like? Medical approval in Germany would follow the standard Medicines Act (AMG) pathway: Preclinical and clinical studies to EMA standard (Phase I–III). Approval application to the Federal Institute for Drugs and Medical Devices (BfArM) or via the centralised EMA procedure. Risk management plan — particularly given the known QT prolongation, a rigorous cardiac screening protocol would be mandatory. G-BA assessment and reimbursement decision. Realistic time horizon: 2028–2030 at the earliest, even under favourable conditions. Until then, the German situation stands: plant legal, therapy not. Treatment in Europe: Where Do German-Speaking Patients Travel? The following information is provided for orientation only — amama does not offer or refer to treatments. German-speaking patients seeking medically supervised ibogaine treatment typically look to three destinations: Netherlands: Established treatment centres have been operating in the greater Amsterdam area for years, with medical staff, pre-screenings and ECG monitoring. Frequently used for opioid dependence. Portugal — Tabula Rasa Retreat (Sintra): Medically supervised program, mandatory cardiological screening, multi-day retreat format. Spain — Madera Sagrada (Órgiva, Andalusia): Smaller centre with a traditional/ceremonial orientation, likewise with medical screening. GITA Safety Standards (Non-Negotiable) The Global Ibogaine Therapy Alliance (GITA) published minimum standards in 2015 that are adhered to by reputable providers. These include: 12-lead ECG before the session, ruling out QT prolongation Cardiac history and, if necessary, echocardiography Electrolyte monitoring (potassium, magnesium) — magnesium supplementation is now standard Discontinuation of interacting medications (SSRIs, methadone, QT-prolonging substances) Continuous monitoring throughout the entire session (12–36+ hours) On-site medical emergency staff ⚠️ Safety notice: Ibogaine may prolong the QT interval and, in rare cases, trigger cardiac arrhythmias. Older case series report approximately 1 life-threatening event per 300 sessions without adequate screening. With full cardiological screening, magnesium supplementation and medical monitoring, this risk drops considerably. Anyone considering treatment should choose exclusively medically supervised settings — never informal or unscreened ceremonies. More on the therapeutic context in the spoke Iboga Therapy. amama's Position amama is a Berlin ethnobotanical smartshop. We sell iboga root bark as a traditional ethnobotanical product — without medicinal or dietary intended purpose, within the framework of German law. We do not offer ibogaine therapies, do not refer to retreats, and do not give dosage recommendations. We support evidence-based research and the right of adult, informed individuals to make their own decisions. We comply with the relevant German regulations (BtMG, NpSG, AMG, LFGB, Health Claims Regulation). For anyone engaging with iboga scientifically or culturally, we provide high-quality material of traceable origin — along with accompanying informational content. Collection Iboga Tabernanthe iboga is a perennial rainforest shrub native to Central Africa, particularly Gabon and Cameroon, where it has been used for centuries in Bwiti initiation ceremoni… → Shop the collection Our selection Iboga Tabernanthe iboga is a perennial rainforest shrub native to Central Africa, particularly Gabon and Cameroon, where it has been used for centuries in Bwiti initiation ceremonies. The root bark… → Shop the collection Further Topics Back to the Iboga Guide | Iboga Effects | Iboga Therapy | Iboga vs. Psilocybin Last updated: 19 April 2026. Legal information provided without warranty — consult a lawyer for individual legal questions. This content is for informational purposes only and does not constitute medical advice. → Ibogaine Compound Profile — chemistry, pharmacology & references
Learn more
Iboga Effects: Mechanism, Alkaloids and What Users Report
This spoke is part of our Iboga Guide. TL;DR — Iboga (Tabernanthe iboga) contains ibogaine as its main alkaloid, a tryptamine-type indole alkaloid with an unusually complex receptor profile: SERT inhibition, NMDA antagonism, kappa-opioid activity and sigma-2 affinity. At 24–36 hours, the experience is significantly longer than with other psychedelics and unfolds in two phases. Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Read more about Ibogaine → > Mechanism: Multi-target pharmacology (SERT, NMDA, κ-opioid, σ2) — no single "key receptor" Duration: 24–36+ hours total experience — unique among psychedelics Two phases: acute visionary phase (0–18h) + introspective reflection phase (18–36h) Alkaloid hierarchy: Ibogaine (main active compound) → Noribogaine (active metabolite, longer half-life) → Tabernanthine, Ibogamine, Coronaridine Safety: QT prolongation is the documented main risk — potentially life-threatening without cardiac pre-screening (approx. 1 in 300 cases). ECG and medical evaluation are mandatory before any ceremonial use. Ibogaine: The Main Active Compound Ibogaine (CAS 83-74-9, molecular formula C₂₀H₂₆N₂O, molecular mass 310.43 g/mol, PubChem CID 3689) is a tryptamine-type indole alkaloid and the pharmacologically most significant constituent of the root bark of Tabernanthe iboga. In the dry mass of the root bark, ibogaine accounts for approximately 3% — a relatively high proportion for plant alkaloids. The remaining alkaloids of the iboga root (more than twelve identified compounds) contribute to the overall effect with different profiles and explain why the effect of the whole root bark ("Total Alkaloid Extract", TA) is not pharmacologically identical to pure ibogaine HCl. Indole alkaloid · Tabernanthe iboga Ibogaine (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Molecular formula: C20H26N2O Molecular weight: 310.4 g/mol CAS: 83-74-9 Compound profile: Ibogaine → Receptor Profile: Why Iboga Works Differently Unlike classical serotonergic psychedelics (psilocybin, LSD, mescaline), which act primarily via the 5-HT2A receptor, ibogaine shows a multi-target profile: Serotonin transporter (SERT) inhibition — structurally comparable to SSRIs, but with a stronger acute effect. This contributes to the sustained mood elevation after the experience. NMDA receptor antagonism — mediates a dissociative component, similar to (but weaker than) ketamine. Associated with the "interruption" of entrenched neuronal patterns. Kappa-opioid receptor activity — agonist. κ-opioid activation is considered central to the visionary quality of the experience and is also observed with salvinorin A (Salvia divinorum). Sigma-2 receptor affinity — studies (including Bhatt et al. 2019) suggest a role in memory reconsolidation, which could explain the biographical-reflective quality of the experience. Nicotinic acetylcholine receptors (α3β4) — antagonism, discussed in the context of the anti-craving effect in addictions. This combination is pharmacologically unique. From this observation, Alper (2012) formulated the hypothesis of a "neuronal reset" — a kind of recalibration of addiction-associated neural pathways. Noribogaine: The Underestimated Metabolite Ibogaine is demethylated in the liver by CYP2D6 to noribogaine. Noribogaine is pharmacologically active, crosses the blood-brain barrier, and has a significantly longer half-life (several days, vs. hours for ibogaine). The sustained anti-craving effect that users report is pharmacokinetically strongly attributed to noribogaine. Clinically relevant: CYP2D6 "poor metabolizers" (approx. 7–10% of the European population) show different effect profiles — one reason why pharmacogenetic screening is standard in reputable treatment centers. Alkaloid Comparison Alkaloid Proportion in root bark Primary mechanism Half-life Effect profile Ibogaine ~3% SERT, NMDA, κ-opioid, σ2 4–7 h Acute visionary phase Noribogaine Metabolite SERT inhibition, κ-opioid several days Sustained mood, anti-craving Tabernanthine ~0.2% κ-opioid (weaker), NMDA short Adjuvant, little researched Ibogamine Traces σ-receptor short Preclinically discussed as cardioprotective Coronaridine ~0.3% Multi-target short In vitro antitumor effects described The Two Phases of the Iboga Experience The ceremonial iboga experience differs structurally from all other psychedelics. Users and researchers consistently describe two clearly distinguishable phases that together can span 24 to 36+ hours. Phase 1: The Acute Visionary Phase (0–18 hours) After a latency of 45–90 minutes, the "flood" sets in — the acute visionary phase. Characteristic features: REM-like rapid eye movements during waking consciousness — EEG patterns resembling waking REM states Vivid autobiographical image sequences — users frequently report a film-like succession of their own life moments ("life review") Physical heaviness, ataxia, nausea — no pleasant bodily sensations. The experience is not recreationally usable. Sound sensitivity — many ceremonies take place in darkened, quiet rooms Confrontational, non-euphoric quality — Bwiti tradition describes this as an "encounter with the ancestors" This phase is intense, demanding, and is consistently described by users as work-intensive, not pleasurable. Phase 2: The Introspective Reflection Phase (18–36 hours) After the visionary phase subsides, a phase of calm wakefulness often lasting more than 12 hours follows. Sleep is barely possible in the first 24 hours. Users describe this phase as: cognitively clear, emotionally calm strongly reflective, with a sense of "ordered thoughts" high insight density, frequently reported as the actual "therapeutic" phase the majority of memory reconsolidation presumably takes place in this phase Only after 30–40 hours does deep sleep set in. Microdose Range: Different Pharmacology Sub-perceptual doses (far below the flood dose) are discussed in some contexts but show a completely different effect profile — primarily mood-modulating, without a visionary phase. The alkaloid ratios (especially ibogaine/noribogaine balance) act differently in this range, and clinical evidence for microdosing is currently minimal. More in the Iboga Guide. From the archive Iboga root bark pieces · Kim Gjerstad · 2011-11-22 Dried root bark pieces of Tabernanthe iboga — the primary traditional preparation used in Bwiti ceremony. Wikimedia Commons · CC BY-SA 4.0 What Users Report (Anecdotal Reports, Strongly Hedged) Studies suggest that users consistently report certain experience patterns. The following account is based on published surveys and observational studies — they are self-reported and do not replace controlled clinical studies. Reported experience patterns: Autobiographical life review — film-like memory sequences, often with a new emotional perspective on early life events Emotional catharsis — crying, release of long-held emotions Reduction of substance craving — particularly consistently reported for opioids and alcohol Sustained mood improvement — users describe effects lasting days to weeks Sense of a "mental reset" — frequently used metaphor Scientific sources documenting such reports: Mash et al. (2018) — observational study on opioid withdrawal with ibogaine, with documented reduction of withdrawal symptoms and craving over 30 days Noller et al. (2018) — New Zealand study, 14 participants with opioid dependence, 12-month follow-up, significant reduction in addiction severity (ASI-Lite scores) Cherian et al. (2024, Nature Medicine, Stanford) — 30 military veterans, ibogaine combined with magnesium, significant improvement of PTSD, depression and anxiety symptoms Important limitation: These studies are small, mostly without a control group, and the participants are strongly self-selected. Anecdotal reports should not be understood as clinical evidence. Larger controlled studies (MAPS, Texas Ibogaine Initiative) are underway. Iboga vs. Classical Psychedelics Iboga differs pharmacologically and phenomenologically markedly from other psychedelics. Iboga Psilocybin LSD Ayahuasca Main mechanism SERT + NMDA + κ-opioid + σ2 5-HT2A agonism 5-HT2A agonism 5-HT2A + MAO inhibition Duration 24–36+ h 4–6 h 8–12 h 4–6 h Phenomenology biographical, life review oceanic, mystical associative, open visionary, purgative Physical demanding, ataxia, nausea mild mild purgative (vomiting) Primary use initiation (Bwiti), addiction therapy therapy, consciousness research therapy, creative religious, therapeutic Legal status DE legal (not in BtMG/NpSG) illegal (Schedule I BtMG) illegal (Schedule I BtMG) DMT illegal; plants grey zone Cardiac risk high (QT prolongation) low low moderate (MAO inhibitor) Perhaps the most important difference: iboga is not a classical 5-HT2A psychedelic. It acts via different receptor pathways, and its effect on memory reconsolidation is mechanistically unique. More on the direct comparison: Iboga vs. Psilocybin. Safety: Risks and Contraindications Iboga has the best-documented cardiac risk profile of all currently discussed psychedelics. This risk is real but largely manageable with appropriate screening — without screening, however, potentially life-threatening. QT Prolongation: The Documented Main Risk Ibogaine blocks hERG potassium channels and can thereby prolong the QT interval on the ECG. Significant QT prolongation can lead to torsades de pointes (a potentially fatal cardiac arrhythmia). Documented deaths (Alper et al. 2012, Koenig & Hilber 2015) are almost exclusively associated with: pre-existing, often undetected heart disease electrolyte disturbances (hypokalemia, hypomagnesemia) co-medication with QT-prolonging substances opioid co-medication during active dependence Approx. 1 in 300 cases may proceed potentially life-threateningly without cardiac pre-screening. With adequate screening, this risk decreases considerably. Absolute Contraindications known heart disease (arrhythmias, long-QT syndrome, heart failure) ongoing SSRI/SNRI medication (serotonin syndrome risk + additive QT prolongation) opioids (additive cardiac risk) benzodiazepines (CYP interaction) MAO inhibitors pregnancy, breastfeeding liver or kidney insufficiency active psychotic disorders Required Screening Before Ceremonial Use The Global Ibogaine Therapy Alliance (GITA) Clinical Guidelines (2015) define a minimum standard: Resting ECG with QTc determination Electrolytes (potassium, magnesium, calcium) Liver values (ALT, AST, γGT) Kidney values (creatinine) Pharmacogenetics (CYP2D6 status, in specialized centers) complete medication and substance history The systematic review by Litjens & Brunt (2016) concluded that the vast majority of documented serious incidents occurred in lay contexts without medical screening — while supervised clinical settings (Netherlands, Mexico, New Zealand) show a significantly more favorable safety profile. Safety notice: Iboga products from amama are traditional botanicals or ethnobotanical collector's items, not therapeutic products and not food or medicinal products. Any form of medical or ceremonial use requires medical supervision with complete cardiac and pharmacological screening. German-speaking users typically travel to treatment centers in the Netherlands or Portugal (e.g. Tabula Rasa Retreat, Sintra). Our selection Iboga Tabernanthe iboga is a perennial rainforest shrub native to Central Africa, particularly Gabon and Cameroon, where it has been used for centuries in Bwiti initiation ceremonies. The root bark… → Shop the collection Back to Overview Back to the Iboga Guide | Iboga & Therapy | Iboga Legal Status Germany | Iboga vs. Psilocybin Last updated: April 2026. This content is for informational purposes only and does not constitute medical advice. → Ibogaine Compound Profile — chemistry, pharmacology & references
Learn more